Posted on

BioMotiv, LLC is the development company of The Harrington Project for Discovery and Development, a $250 million initiative to revolutionize how new breakthrough drugs are advanced to market. By aligning the upstream efforts of the University Hospitals Case Medical Center’s Harrington Discovery Institute with the downstream development efforts of BioMotiv, The Harrington Project seeks to accelerate the therapeutic innovation process for the benefit of patients globally. BioMotiv intends to raise $100 million in total initial capital as it builds a portfolio of novel discoveries in-licensed from academic medical centers associated with The Harrington Project and other sources. The company has designed a business model that facilitates efficient execution of earlier-stage drug development programs with the objective of out-licensing these significantly enhanced assets to biopharmaceutical companies or venture firms for later-stage development and commercialization.